ACUTE PULMONARY HISTOPLASMOSIS [45-2] ADHESION [119-1], [156-2] ADHESION MOLECULES [134-1] ADJUVANT [148-1] ADVERSE EFFECTS [44-1] AEROSOL [122-1] AGROBACTERIUM TUMEFACIENS [92-5] AIDS [152-1] AJELLOMYCETACEAE [96-2] ALBUMIN [146-1] ALPHA GLUCANASE [115-1] ALPHA-1,3-GLUCAN [115-1] ALTENUSIN [84-1] ALTERNATIVE OXIDASE [156-1] AMBISOME [131-1] AMPHOTERICIN B [57-1] ANERGY [74-1] ANPHOTERICIN B [131-1] ANTIBODIES [174-1] ANTIBODY [125-1], [149-1] ANTIFUNGAL [39-1], [48-3], [49-1], [69-1], [70-1], [84-2] ANTIFUNGAL ACTIVITY [11-1], [75-1] ANTIFUNGAL DEVELOPMENT [124-1] ANTIFUNGAL SUSCEPTIBILITY [126-2], [126-3] ANTIFUNGAL SUSCEPTIBILITY PROFILE [126-4] ANTIFUNGAL THERAPY [99-1] ANTISENSE RNA [92-1] ANTIZIME [115-2] ARGENTILACTONE [76-1] ARMADILLOS [122-1] ARNA SILENCING [156-1] ARTHRITIS [73-12] ARTICULAR [73-12] ARTINM [65-1], [65-2] ASPERGILLOSIS [150-1] ASPERGILLUS FUMIGATUS [19-3], [31-1], [32-1], [34-2] AUTHENTIC PGE2 [64-1] AUTOPHAGY [93-1] AZOLE COMPOUNDS [57-1] AZOLE DRUGS [172-1] AZOLES [135-1]
BACCHARIS DRACUNCULIFOLIA [84-2] BIOCHEMICAL [43-2] BIOCHEMISTRY [147-1] BIOINFORMATICS [155-1] BIOLOGY [147-1] BLAST [104-3] BLOOD GROUP [137-3] BLOOD GROUP ANTIGENS [137-6] BONE [152-2] BRAZIL [112-2] BRY2 [38-1]
CALCINEURIN [110-1], [110-2] CANDIDA ALBICANS [126-3] CANDIDA DUBLINIENSIS [126-4] CANDIDA PARAPSILOSIS COMPLEX [126-1] CANDIDA SPP [126-2] CARBOHYDRATE [158-1] CARBONIC ANHYDRASE [23-1] CAS [21-1] CATIONIC LIPID [148-1] CELL VIABILITY [78-1] CELL WALL [18-2], [19-1], [19-2], [84-1], [115-1], [120-1] CELULAS ENDOTELIAIS [34-2] CHAPERONE [19-3] CHARACTERIZATION [112-1] CHEMOKINE [89-1] CHEMOKINE RECEPTORS [134-1] CHEMOTAXIS [159-1] CHILDREN [24-2], [146-1] CHITIN-BINDING [14-1] CHITINASE [14-1] CHLAMYDOSPORE [27-1] CHROMOBLASTOMYCOSIS [131-2], [135-1] CHROMOSOMES [136-1] CITOCINAS [88-1] CITOKINES [108-1] CLASS II TRANSPOSONS [106-3] CLINICAL AND TREATMENT ASPECTS [127-1], [127-2] CO MORBIDITY [152-3] CO2 [23-1] COAGULATION SYSTEM [80-1] COCL2 [22-1] COMPARATIVE GENOMICS [48-3], [124-1], [155-1] CONVENTIONAL DIAGNOSIS [162-1] COPIA-LIKE RETROTRANSPOSON [129-1] COPPER DEPRIVATION [95-1] CORTICOSTEROIDS [143-1] COTRIMOXAZOLE [44-1] CRYPTIC SPECIES [96-2] CRYPTOCOCCOSIS [127-1] CYCLONE SAMPLER [102-1] CYCLOSPORIN A [73-11] CYTOKINE [5-1] CYTOKINE PROFILES [101-2] CYTOKINES [75-1], [81-1], [105-2], [111-1], [163-3], [170-2], [170-3], [174-2] CYTOTOXICITY [153-1]
DATABASE [45-3] DENDRITIC CELL [103-1] DENDRITIC CELLS [117-1], [163-3] DIAGNOSIS [45-4], [46-1], [144-1], [162-1] DIAGNOSTIC [93-2] DIMORPHIC FUNGI [155-1] DIMORPHISM [93-1], [110-1], [113-1] DIOXYGENASE [64-1] DIRECT EXAMINATION [45-5] DISEASE RELAPSE [43-1] DISSEMINATED PARACOCCIDIOIDOMYCOSIS [143-1] DNA [93-2] DNA TRANPOSONS [106-3] DNA TRANSPOSONS [106-1] DNA VACCINE [131-2] DNA-HSP65 [131-2] DOSAGEM [88-1] DOUBLE AGAR GEL IMMUNODIFFUSION TEST-DID [43-1] DOUBLE IMMUNODIFFUSION [45-2], [45-6] DOUBLE IMMUNODIFFUSION ASSAY [45-5] DRUG AND VACCINE DEVELOPMENT [165-1] DRUG TARGETS [31-1], [48-3], [49-1] DRUGS [39-1] DYSPHONIA [73-9] DYSPNEA [73-9]
ECOLOGY [122-1] ELISA [144-1] EMPHYSEMA [137-1] EMSA [120-1] ENDEMIC MYCOSES [162-1] ENDONUCLEASE DOMAIN [96-2] ENOLASE 54 KDA [119-1] ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA [43-1] ENZYMES [32-1] EOSINOPHILS [159-1] EPIDEMIOLOGICAL SURVEY [152-1] EPIDEMIOLOGY [45-7], [142-3], [151-1], [172-1] EPIDEMIOLOGYCAL ANALYSIS [45-3] ERGOSTEROL [84-2] ESTRADIOL [145-1] EXPERIMENTAL ARTHRITIS [73-10] EXPERIMENTAL MODEL [131-2] EXPRESSION ANALYSIS [20-1] EXTINCTION CULTURE [102-1] EXTRACELLULAR MATRIX PROTEIN [92-3] EXTRACELLULAR VESICLES [16-1], [16-3], [54-1]
FERRIC REDUCTASES [1-1] FIBRINOGEN [80-1] FIBROSIS [107-1], [170-1] FLOW CYTOMETRY [159-1] FLUCONAZOLE [114-1] FORM TRANSITION [145-1] FORMAS CLINICAS [88-1] FT-IR [93-2] FUNGAL [89-1] FUNGAL ARTHRITIS [73-10] FUNGAL INFECTION [118-1] FUNGAL STRAINS [170-3] FUNGI [165-1] FUNGUS-HOST INTERACTION [33-1] FUSARIOSIS [150-1]
GAMMA IRRADIATION [35-2] GAMMA-IFN [170-1] GC-MS [158-1] GENE EXPRESSION [37-1], [145-1] GENE FUNCTION [104-3] GENE SILENCING [78-1], [92-1], [92-5] GENOMICS [104-1], [104-3] GENOTYPING [126-3] GLUCOSYLCERAMIDE [157-1] GLYCOLIPIDS [105-1] GP43 [24-1], [24-2], [46-1], [56-1], [149-1], [152-1] GP75 [121-1] GRANULOMATOUS LESIONS [170-2], [170-3] GRANULYSIN [154-1]
HELIUM-NEON (HENE) LASER [170-4] HEMATOLOGICAL [43-2] HEMOGLOBIN [1-1], [146-1] HISTOPATHOLOGY [107-1] HISTOPLASMA [125-1], [139-1] HISTOPLASMA CAPSULATUM [45-2], [111-1] HISTOPLASMOSIS [45-4], [127-2] HIV-INFECTED INDIVIDUALS [126-1], [126-2], [126-3] HIV-INFECTED INDIVIDUALS. [126-4] HLA DR/DQ [163-3] HOST DEFENSE [111-1] HOST-FUNGUS INTERACTION [20-2] HPLC [64-1] HSP-90 [110-1], [110-2] HSP70 GENE [106-2] HSP90 [78-1] HUMAN MONOCYTES [63-1], [75-1] HYDROLASE [156-2] HYDROXAMATE [21-1] HYPHAE [19-3] HYPOXIA [22-1] HYPTIS OVALIFOLIA [76-1]
IFN-GAMMA [174-2] IL-17 [134-1] IL-18 [11-1], [63-1] IMMUNE RESPONSE [107-1], [134-1], [148-1] IMMUNITY [89-1] IMMUNOASSAYS [45-6] IMMUNOBLOT [92-1] IMMUNOBLOTTING [45-2], [45-4], [45-6] IMMUNOCOMPETENT PATIENT [45-4] IMMUNOCOMPROMISED PATIENTS [137-5] IMMUNODIAGNOSIS [45-7] IMMUNODIFFUSION [133-2] IMMUNODIFFUSION ASSAY [45-3] IMMUNODIFFUSION TEST [137-2] IMMUNOHISTOCHEMISTRY [108-1] IMMUNOHISTOPATHOLOGY [101-2] IMMUNOLOCALIZATION [119-1] IMMUNOMODULATION [81-1], [101-1], [118-1], [167-1] IMMUNOSUPPRESSED [150-1] IMMUNOSUPPRESSION [73-11] INCIDENCE [172-1] INCREASED PERFORMANCE [50-1] INDEX KAPPA [45-2] INDOLEAMINE-2,3-DIOXYGENASE [130-1] INFECTION [27-1] INFECTION AND [163-3] INFLAMMATORY CYTOKINES [33-1] INFRAEPLIGOTE [73-9] INHIBITION [42-1], [76-1] INNATE IMMUNITY [132-1] INTERAÇAO FUNGO-HOSPEDEIRO [6-1], [34-2] INTRADERMAL SKIN TESTS [151-1] INTRADERMAL TEST [144-1] INVASIVE MYCOSIS [150-1] IRON [18-3] IRON HOMEOSTASIS [1-1] IRON METABOLISM [100-1] IRON SOURCES [100-1] IRON UPTAKE [21-1] ISOCITRATE LYASE [42-1], [76-1] ISOLATE PB 01 [131-3] ISOLATE PB 18 [131-3] ISOLATION [27-1] ITAIPU LAKE [73-8], [73-13] ITRACONAZOL [81-1] ITRACONAZOLE [44-1], [69-2]
KAPPA INDEX [45-6] KARYOTYPE [136-1] KINASES [104-1] KINETOPLASTIDS [165-1]
LATEX AGGLUTINATION [149-1] LATEX AGGLUTINATION TEST [50-1] LC-MS/MS [16-2] LECTIN [65-1], [167-1] LESION [143-2] LESIONS [170-4] LEUKOTRIENES [111-1] LIPID MEDIATORS [111-1] LIPIDOME [30-1] LIPIDOMIC [16-3] LIPIDS [19-1], [110-2] LIVER [146-1] LUMIRACOXIB [170-1] LUNG [89-1], [103-1], [161-1] LUNG EPITHELIAL CELLS [33-1] LUNG INFECTION [20-2] LYMPHOCYTES [130-1] LYMPHOCYTES PROLIFERATION [105-1]
MACROFAGOS MURINOS [6-1] MACROPHAGES [92-3] MALATE SYNTHASE [42-1] MANNAN [132-1] MANNOSE RECEPTOR [11-1], [63-1], [132-1] MASS SPECTROMETRY [4-1], [18-1], [18-2], [64-1] MAT 1-1 [92-2] MAT1-2 [92-2] MATING [90-1], [142-1], [142-2] MATING TYPE [92-2] MATO GROSSO DO SUL [24-1] MDJ1P [19-3] MEC [6-1] MELANIN [135-1] MELANIZED FUNGI [135-1] METABOLISM [104-1] MICROARRAY [145-1] MINIMUM INHIBITORY CONCENTRATION [57-1] MOLECULAR [147-1] MOLECULAR DIAGNOSIS [162-1] MOLECULAR IDENTIFICATION [137-4] MOLECULAR MODELING [49-1] MONOCLONAL ANTIBODY [157-1] MONOCYTES [11-1], [105-1] MONOCYTES EFFECTOR MECHANISMS [59-1] MORPHOLOGICAL CHARACTERISTICS [66-1] MORPHOLOGY [131-3] MORTALITY [73-8] MUTATION [139-1] MYCELIUM [110-1] MYCOLOGICAL DIAGNOSIS [45-5] MYCOSIS [73-8], [73-12], [73-13]
N-ACETYL-β-D-GLUCOSAMINIDASE [10-1] N-GLYCAN [167-1] N-GLYCANS [10-1] NANOPARTICLES [131-1] NATURAL KILLER CELLS [153-1] NEGATIVE SERUM [137-2] NEONATE [73-14] NESTED-PCR [45-4] NITRIC OXIDE [109-1] NITROSATIVE STRESS [3-1] NK CELLS [154-1] NKT CELLS [105-2] NON-AIDS PATIENTS [127-1], [127-2]
OENOTHEIN B [69-1] OMICS [165-1] ONYGENALES [155-1] ORAL CAVITY [126-1] ORNITHINE DECARBOXYLASE [115-2] OSTEOARTICULAR [133-2] OSTEOLYSIS [152-2] OXIDATIVE STRESS [4-1], [37-1]
P. BRASILIENSIS [8-1], [74-1], [102-1], [105-1], [143-2], [156-1], [156-2] P. LUTZII [143-2] P10 [56-1], [74-1], [148-1] PADG_03347 [14-1] PARACOCCIDIODES BRASILIENSIS [152-1] PARACOCCIDIODES LUTZII [49-1] PARACOCCIDIODIC INFECTION [24-2] PARACOCCIDIODOMYCOSIS [35-2], [84-1], [152-3] PARACOCCIDIOIDES [56-1], [106-3], [142-2], [145-1], [147-1] PARACOCCIDIOIDES BRASILENSIS [6-1] PARACOCCIDIOIDES BRASILIENSIS [4-1], [5-1], [10-1], [11-1], [13-1], [14-1], [16-1], [16-2], [16-3], [18-1], [18-2], [19-1], [19-2], [19-3], [20-1], [22-1], [23-1], [24-1], [24-2], [27-1], [33-1], [35-2], [39-1], [42-1], [43-1], [44-1], [45-7], [54-1], [57-1], [59-1], [63-1], [64-1], [66-1], [69-1], [69-2], [70-1], [73-8], [73-9], [73-10], [73-11], [73-12], [73-13], [73-14], [75-1], [76-1], [78-1], [80-1], [84-2], [92-1], [92-2], [92-3], [92-5], [92-6], [100-1], [101-2], [112-3], [113-1], [117-1], [119-1], [120-1], [122-1], [129-1], [130-1], [132-1], [142-1], [148-1], [157-1], [158-1], [174-1] PARACOCCIDIOIDES LUTZII [46-1], [59-1], [106-2], [142-1], [142-3] PARACOCCIDIOIDOMICOSE [24-1] PARACOCCIDIOIDOMYCOSIS [43-1], [43-2], [44-1], [45-3], [45-5], [45-6], [45-7], [50-1], [65-2], [73-8], [73-9], [73-10], [73-11], [73-12], [73-13], [73-14], [74-1], [95-1], [105-2], [107-1], [108-1], [114-1], [117-1], [131-1], [133-2], [134-1], [137-1], [137-3], [137-5], [137-6], [144-1], [146-1], [149-1], [151-1], [152-2], [154-1], [159-1], [163-3], [174-2] PARACOCCIDIOIDOMYCOSIS-PATIENTS [99-1] PARACOCCIDIOIMYCOSIS [153-1] PARACOCCIDIOMYCOSIS [172-1] PATHOGENESIS [3-1], [125-1] PATHOGENIC FUNGUS [37-1], [129-1] PATHOGENICITY [93-1], [156-1] PATIENT [143-2] PBGP43 [92-1], [92-3], [92-6] PBP27 [92-5], [92-6] PCR; [66-1] PENTOXIFYLLINE [101-1] PEROXIREDOXIN [19-2] PET28A [116-1] PFGE [136-1] PHAEOHYPHOMYCOSIS [135-1] PHAGE DISPLAY [121-1] PHASE TRANSITION [8-1] PHENOTYPIC SWITCH [90-1] PHENOTYPING [137-6] PHEROMONE [142-2] PHOSPHOLIPIDS [19-1] PHOSPHORYLATION [109-1] PHOTODYNAMIC THERAPY [37-1] PHYLOGENETIC SPECIES 3 [106-1] PHYLOGENY [142-3] PKA [8-1] PLASMA PROTEINS [80-1] PLGA [131-1] POLYMERASE CHAIN REACTION [106-2] POLYSACCHARIDES [54-1] POST-GENOMIC ANALYSIS [124-1] PREGNANCY [73-14] PROFILE [73-13] PROFILE PROTEIN [66-1] PROTEASOME [115-2] PROTEIN EXPRESSION [112-3] PROTEINA GPI [6-1] PROTEOME [3-1], [4-1], [18-2], [18-3], [20-1], [31-1], [100-1] PROTEOMIC [112-3] PROTEOMIC ANALYSIS [95-1] PRX1P [19-2] PULMONARY FIBROSIS [137-1] PULMONARY PARACOCCIDIOIDOMYCOSIS [101-1] PURIFICATION [27-1]
RADIOLOGY [73-10] RAS GTPASE [38-1], [116-1] RBD-GST PROBE [38-1] RDA [70-1] REACTIVE OXYGEN SPECIES [37-1], [109-1] REAL TIME PCR [92-2], [92-5], [92-6] REGIONAL STRAINS [66-1] REGULATION OF GENE EXPRESSION [120-1] RENAL TRANSPLANT [137-5] REPRESENTATIONAL DIFFERENCE ANALYSIS [20-2] RESPIRATORY SEQUELAE [161-1] REVERSE-PHASE HPLC [21-1] RHINOSINUSITIS [137-4] RNA [54-1] RNA INTERFERENCE [92-6] RNAI [139-1] RODENT [89-1] RURAL SETTLEMENTS [24-1], [24-2]
SACCHAROMYCES CEREVISIAE [13-1] SCHISTOSOMA MANSONI [174-2] SCHIZOPHYLLUM COMMUNE [137-4] SECRETION [139-1] SECRETOME [16-2], [18-1], [30-1], [32-1] SELECTION [113-1] SELECTION OF TOLERANT [114-1] SEROLOGICAL DIAGNOSIS [137-2] SEROLOGY [112-1] SEXUAL REPRODUCTION [90-1] SHORT READ SEQUENCING [155-1] SIDEROPHORES [100-1] SIGNALING PATHWAYS [116-1] SILENCING [92-3] SKIN TEST [152-1] SOMATIC ANTIGEN [174-1] SORO [88-1] SOROCABA [45-3] SPECIATION [142-1], [147-1] SPIDER WEBS [122-1] SPLENECTOMY [73-11] SPLICING DOMAIN [96-2] SPOROTHRIX [112-1], [112-2] SPOROTHRIX BRASILIENSIS [136-1] SPOROTHRIX GLOBOSA [112-1] SPOROTHRIX MEXICANA [112-2] SPOROTHRIX SCHENCKII [136-1] SPOROTRICHOSIS [112-2] ST2 [118-1] STEROLS [19-1] SULFAMETHOXAZOLE [70-1], [113-1] SULFAMETHOXAZOLE-TRIMETHOPRIM [74-1] SULFAMIDE DRUGS [172-1] SURFACE ANTIGENS [137-3] SURFACE PROTEINS [18-3] SUSCEPTIBILITY AND RESISTANCE [170-2] SUSCEPTIBILITY TESTS [57-1] SYNTENY [104-3] SYNTHETIC PEPTIDES [121-1] SYSTEMS BIOLOGY [165-1]
T CELL [103-1] T LYMPHOCYTES SUBSETS [99-1] TAXONOMY [112-1], [112-2] TC1/MARINER [106-1] TETRACYCLIN [170-1] TH1 [174-2] TH1 IMMUNITY [167-1] TH17 RESPONSE [5-1] TH2 [174-1] THERAPEUTIC TARGET [96-2] THIOL-SPECIFIC ANTIOXIDANT [19-2] THIOSEMICARBAZIDE [42-1] TLR2 [65-1], [65-2], [154-1] TLR4 [65-1] TLRS [63-1] TOLL-LIKE RECEPTOR [167-1] TRANSCRIPTIONAL ANALYSIS [39-1] TRANSCRIPTIONAL PROFILE [69-2] TRANSCRIPTOME [3-1], [69-1], [70-1] TRANSFORMATION [139-1] TREATED PARACOCICDIOIDOMYCOSIS [161-1] TREATMENT [143-1], [170-1], [170-4] TREG CELLS [130-1] TREM A-H [106-1] TUBERCULOSIS [152-3] TWO DIMENSIONAL GEL ELECTROPHORESIS [112-3] TWO-DIMENSIONAL GEL ELECTROPHORESIS [4-1]
ULTRASTRUCTURE [131-3] UNTREATED PATIENTS [43-2]
VACCINE [13-1], [35-2], [56-1] VARIABLES [43-2] VESICLES [16-2], [30-1], [110-2] VIRTUAL SCREENING [49-1] VIRULENCE [73-14], [112-3], [119-1], [156-2], [170-3] VIRULENCE FACTOR [174-1]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2011 - XI International Meeting on Paracoccidioidomycosis. All rights reserved.
By ADALTECH